GWP
CLSD

Gen-Wealth Partners’s Clearside Biomedical CLSD Stock Holding History

Gen-Wealth Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-667
Closed -$8K – 690
2025
Q2 		$8K Buy
+667
New +$8.28K ﹤0.01% 474

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $6.15B AUM 22.62% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Gen-Wealth Partners's CLSD Position: Q3 2025 in Review

Gen-Wealth Partners sold out of Clearside Biomedical (CLSD) in Q3 2025, closing a stake of 667 shares — an estimated $8K sold.

Gen-Wealth Partners first reported a position in CLSD in Q2 2025 and held it in 1 quarter. The position peaked at $8K in Q2 2025. 26 funds tracked by Wall St. Rank hold CLSD as of Q3 2025.

  • Gen-Wealth Partners reported no remaining Clearside Biomedical position as of Q3 2025 after selling out during the quarter.
  • Gen-Wealth Partners sold 667 Clearside Biomedical shares in Q3 2025, an estimated $8K.
  • Gen-Wealth Partners first reported a position in Clearside Biomedical in Q2 2025 and held it in 1 quarter.
  • Gen-Wealth Partners's Clearside Biomedical position peaked at $8K in Q2 2025.
  • 26 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2025.

Based on Gen-Wealth Partners's 13F filing for Q3 2025, filed 14 Nov 2025.